YU84303A - Postupak dobijanja cetp inhibitora - Google Patents

Postupak dobijanja cetp inhibitora

Info

Publication number
YU84303A
YU84303A YU84303A YUP84303A YU84303A YU 84303 A YU84303 A YU 84303A YU 84303 A YU84303 A YU 84303A YU P84303 A YUP84303 A YU P84303A YU 84303 A YU84303 A YU 84303A
Authority
YU
Yugoslavia
Prior art keywords
methods
cetp inhibitors
preparing
preparing cetp
inhibitors
Prior art date
Application number
YU84303A
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Robert William Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU84303A publication Critical patent/YU84303A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Ovaj pronalazak se odnosi na postupke dobijanja odredjenih inhibitora holesteril estar transfer proteina (CETP) i njihove odgovarajuće intermedijere.[This invention relates to methods for preparing certain cholesteryl ester transfer protein (CETP) inhibitors IA or IB and intermediates related thereto.
YU84303A 2001-04-30 2002-04-08 Postupak dobijanja cetp inhibitora YU84303A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28752201P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
YU84303A true YU84303A (sh) 2006-05-25

Family

ID=23103272

Family Applications (2)

Application Number Title Priority Date Filing Date
YU84403A YU84403A (sh) 2001-04-30 2002-04-08 Jedinjenja korisna kao intermedijeri za derivate-4- aminohinolina
YU84303A YU84303A (sh) 2001-04-30 2002-04-08 Postupak dobijanja cetp inhibitora

Family Applications Before (1)

Application Number Title Priority Date Filing Date
YU84403A YU84403A (sh) 2001-04-30 2002-04-08 Jedinjenja korisna kao intermedijeri za derivate-4- aminohinolina

Country Status (25)

Country Link
US (3) US6689897B2 (sh)
EP (2) EP1383734B1 (sh)
JP (2) JP3924251B2 (sh)
KR (2) KR100639745B1 (sh)
CN (3) CN1267411C (sh)
AR (3) AR035963A1 (sh)
AT (2) ATE316957T1 (sh)
AU (1) AU2002253448B2 (sh)
BR (2) BR0209291A (sh)
CA (2) CA2445623A1 (sh)
CZ (2) CZ20032900A3 (sh)
DE (2) DE60210265T2 (sh)
DK (2) DK1425270T3 (sh)
ES (2) ES2259080T3 (sh)
HK (1) HK1062294A1 (sh)
HU (2) HU225777B1 (sh)
IL (2) IL157544A0 (sh)
MX (2) MXPA03009936A (sh)
PL (2) PL366584A1 (sh)
PT (1) PT1425270E (sh)
RU (2) RU2259355C2 (sh)
TW (1) TWI250974B (sh)
WO (2) WO2002088085A2 (sh)
YU (2) YU84403A (sh)
ZA (2) ZA200306600B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US20040002615A1 (en) * 2002-06-28 2004-01-01 Allen David Robert Preparation of chiral amino-nitriles
JP2006021999A (ja) * 2002-07-12 2006-01-26 Kaneka Corp 光学活性β−アミノニトリル化合物およびその対掌体アミド化合物の製造方法
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003277285B2 (en) 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
DE60331873D1 (de) 2002-12-20 2010-05-06 Pfizer Prod Inc Dosierungsform enthaltend einen CETP-Hemmer und einen HMG-CoA Reduktase Hemmer
JP4644658B2 (ja) * 2003-02-18 2011-03-02 高砂香料工業株式会社 光学活性テトラヒドロキノリン類の製造方法
WO2004083166A1 (ja) * 2003-03-17 2004-09-30 Kaneka Corporation （ｒ）－３－［４－（トリフルオロメチル）フェニルアミノ］－ペンタン酸アミド誘導体の製造法
US7223859B2 (en) 2003-03-17 2007-05-29 Pfizer Inc. Method for producing (R)-3-[4-(trifluoromethyl) phenylamino]-pentanoic acid amide derivative
EP1670446A2 (en) 2003-09-26 2006-06-21 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
CN101018770A (zh) * 2004-04-07 2007-08-15 千禧药品公司 炎性疾病治疗用pgd2受体拮抗剂
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
DE102004031656A1 (de) * 2004-06-30 2006-01-19 Merck Patent Gmbh Tetrahydrochinoline
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20100041911A1 (en) * 2005-06-20 2010-02-18 Astrazeneca Ab Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
DE102006031262A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006031149A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
DE102006032391A1 (de) * 2006-07-04 2008-01-17 Merck Patent Gmbh Fluortenside
DE102006031143A1 (de) * 2006-07-04 2008-01-24 Merck Patent Gmbh Fluortenside
DE102006031151A1 (de) * 2006-07-04 2008-01-10 Merck Patent Gmbh Fluortenside
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
JP2011256110A (ja) * 2008-09-30 2011-12-22 Takeda Chem Ind Ltd ヘキサヒドロピロロキノリンの製造法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
WO2012141487A2 (en) 2011-04-12 2012-10-18 Chong Kun Dang Pharmaceutical Corp. Cycloalkenyl aryl derivatives for cetp inhibitor
CA2841117A1 (en) 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
HUE033790T2 (en) 2013-01-31 2017-12-28 Chong Kun Dang Pharmaceutical Corp CETP inhibitor biaryl or heterocyclic biaryl substituted cyclohexene derivatives
CN105706289A (zh) * 2013-11-11 2016-06-22 隆萨有限公司 利用路易斯酸制备第13族元素的氰基化合物的方法
WO2016024858A1 (en) * 2014-08-12 2016-02-18 Dezima Pharma B.V. Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives
CN105294559B (zh) * 2015-06-24 2017-11-14 厦门法茉维特动物药业有限公司 一种医药中间体4‑氨基喹啉类化合物的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2336691C (en) 1998-07-10 2009-02-10 Massachusetts Institute Of Technology Ligands for metals and metal-catalyzed processes
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
DE60209004D1 (de) 2006-04-13
BR0209291A (pt) 2004-07-13
US6689897B2 (en) 2004-02-10
KR100591998B1 (ko) 2006-06-22
CN1529696A (zh) 2004-09-15
WO2002088069A3 (en) 2003-02-20
EP1383734B1 (en) 2006-02-01
HK1062294A1 (en) 2004-10-29
CA2445693A1 (en) 2002-11-07
ES2259080T3 (es) 2006-09-16
HUP0304041A2 (hu) 2004-04-28
ZA200306600B (en) 2004-08-25
DE60210265D1 (de) 2006-05-18
AR035963A1 (es) 2004-07-28
KR20040015200A (ko) 2004-02-18
KR20040030603A (ko) 2004-04-09
RU2259355C2 (ru) 2005-08-27
DE60210265T2 (de) 2006-10-12
DE60209004T2 (de) 2006-09-28
PL366700A1 (en) 2005-02-07
ES2256461T3 (es) 2006-07-16
CA2445623A1 (en) 2002-11-07
CN1297541C (zh) 2007-01-31
EP1425270B1 (en) 2006-03-29
RU2265010C2 (ru) 2005-11-27
CN1267411C (zh) 2006-08-02
AU2002253448B2 (en) 2007-07-05
IL157546A0 (en) 2004-03-28
HUP0304039A3 (en) 2005-10-28
HU225777B1 (en) 2007-08-28
CN1680292A (zh) 2005-10-12
CN100357265C (zh) 2007-12-26
AR044706A2 (es) 2005-09-21
CZ20032900A3 (cs) 2004-06-16
EP1425270A2 (en) 2004-06-09
RU2003131871A (ru) 2005-04-10
PL366584A1 (en) 2005-02-07
JP3924251B2 (ja) 2007-06-06
JP3924250B2 (ja) 2007-06-06
MXPA03009936A (es) 2004-01-29
KR100639745B1 (ko) 2006-10-30
JP2004527556A (ja) 2004-09-09
WO2002088085A3 (en) 2004-03-25
JP2004531541A (ja) 2004-10-14
AR036331A1 (es) 2004-09-01
BR0209238A (pt) 2004-06-15
MXPA03009935A (es) 2004-01-29
ZA200306599B (en) 2004-10-22
WO2002088085A2 (en) 2002-11-07
CZ20032898A3 (cs) 2004-07-14
PT1425270E (pt) 2006-07-31
EP1383734A2 (en) 2004-01-28
YU84403A (sh) 2006-08-17
US20030216576A1 (en) 2003-11-20
ATE316957T1 (de) 2006-02-15
DK1383734T3 (da) 2006-05-15
US6600045B2 (en) 2003-07-29
IL157544A0 (en) 2004-03-28
RU2003131870A (ru) 2005-01-27
WO2002088069A9 (en) 2003-12-04
CN1505609A (zh) 2004-06-16
ATE321755T1 (de) 2006-04-15
US20020177716A1 (en) 2002-11-28
HUP0304041A3 (en) 2005-08-29
TWI250974B (en) 2006-03-11
US6706881B2 (en) 2004-03-16
HUP0304039A2 (hu) 2004-03-29
DK1425270T3 (da) 2006-07-03
US20030073843A1 (en) 2003-04-17
WO2002088069A2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
YU84303A (sh) Postupak dobijanja cetp inhibitora
ZA200308561B (en) Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors.
AU2002359522A8 (en) Compositions and methods of selective nucleic acid isolation
GB0322515D0 (en) Enzymes for specific fragmentation of proteins
EP1572863A4 (en) METHOD FOR IDENTIFYING INHIBITORS G-PROTEIN-COUPLED RECEPTOR SIGNALS
AU2002316137A1 (en) Method of determining protein interaction inhibitors
MXPA00010722A (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
BG105009A (en) Method for producing 4-carboxyamino-2-substituted 1,2,3,4-tetrahydroquinoline
SE5292304T3 (sh)
MXPA05009848A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
GB0011358D0 (en) Novel use
HK1088016A1 (en) Isolated fluorescent protein from clytia gregaria cgfp and use thereof
AU2002258437A1 (en) Peptide deformylase inhibitors
AU2002322035A1 (en) Peptide deformylase inhibitors
AU2002255635A1 (en) Peptide deformylase inhibitors
PT1594879E (pt) Processo e intermediários para a preparação de olanzapina
ATE433953T1 (de) Peptiddeformylaseinhibitoren
AU2002325827A1 (en) Compositions and methods for detecting or regulating cholesteryl ester transfer protein
AU2002364192A8 (en) Method of identifying novel proteins
HK1069836A1 (en) Compositions and methods for wt1 specific immunotherapy wt1
AU2002361399A8 (en) Method for the quantitative determination of gene expression